Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,300 JPY | +1.34% | +2.77% | -8.59% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 8.37 for the current year and 9.92 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.59% | 6.86B | B+ | ||
+19.62% | 43.34B | B- | ||
+20.44% | 21.96B | B+ | ||
+10.86% | 14.09B | - | ||
+13.07% | 13.64B | B+ | ||
+37.46% | 11.43B | B | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ | ||
-4.29% | 4.71B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4528 Stock
- Ratings Ono Pharmaceutical Co., Ltd.